Trial · NCT03359473
Outcomes56
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 56
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | Baseline (Day 1, Pre-dose), Days 14, 28, 56 and 90 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Millimeters of mercury | MEAN |
| PRIMARY | Change From Baseline in Heart Rate | Baseline (Day 1, Pre-dose), Days 14, 28, 56 and 90 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Beats per minute | MEAN |
| PRIMARY | Change From Baseline in PR Interval, QRS Duration, QT Interval, QT Interval Corrected for Heart Rate by Fridericia's Formula (QTcF) and QT Interval Corrected for Heart Rate by Bazett's Formula (QTcB) | Baseline (Day 1, Pre-dose), Days 14, 28, 56 and 90 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Milliseconds | MEAN |
| PRIMARY | Number of Participants With Grade Increase Post-Baseline Relative to Baseline in Hematology Parameters | Baseline (Day 1, Pre-dose) and up to Day 132 | Safety Population. Only those participants with data available at the specified data points were analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Grade Increase Post-Baseline Relative to Baseline in Clinical Chemistry Parameters | Baseline (Day 1, Pre-dose) and up to Day 132 | Safety Population. Only those participants with data available at the specified data points were analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Change From Baseline in Urinalysis Parameter; Specific Gravity: Placebo-Female Participants | Baseline (Day 1, Pre-dose), Days 28, 56 and 90 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Ratio | MEAN |
| PRIMARY | Change From Baseline in Urinalysis Parameter; Specific Gravity: GSK2881078 1.0 mg- Female Participants | Baseline (Day 1, Pre-dose), Days 14 and 90 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Ratio | MEAN |
| PRIMARY | Change From Baseline in Urinalysis Parameter; Specific Gravity: Male Participants | Baseline (Day 1, Pre-dose), Days 28 and 90 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Ratio | MEAN |
| PRIMARY | Change From Baseline in Urinalysis Parameter; Potential of Hydrogen (pH): Placebo- Female Participants | Baseline (Day 1, Pre-dose), Days 28, 56 and 90 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | pH | MEAN |
| PRIMARY | Change From Baseline in Urinalysis Parameter; pH: GSK2881078 1.0 mg- Female Participants | Baseline (Day 1, Pre-dose), Days 14 and 90 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | pH | MEAN |
| PRIMARY | Change From Baseline in Urinalysis Parameter; pH: Male Participants | Baseline (Day 1, Pre-dose), Days 28 and 90 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | pH | MEAN |
| PRIMARY | Number of Participants With Urinalysis Dipstick Results Post-Baseline Relative to Baseline | Baseline (Day 1, Pre-dose) and up to Day 132 | Safety Population. Only those participants with data available at the specified data points were analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events | Up to Day 132 | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Percentage Change From Baseline in Maximum Leg Press Strength Following 1 Repetition Maximum (1-RM) at Day 28 | Baseline (Day 1, Pre-dose), Day 28 | Analysis Population. Only those participants with data available at the specified data points were analyzed. | Percentage change | MEAN |
| PRIMARY | Percentage Change From Baseline in Maximum Leg Press Strength Following 1 Repetition Maximum (1-RM) at Day 56 | Baseline (Day 1, Pre-dose), Day 56 | Analysis Population. Only those participants with data available at the specified data points were analyzed. | Percentage change | MEAN |
| PRIMARY | Percentage Change From Baseline in Maximum Leg Press Strength Following 1 Repetition Maximum (1-RM) at Day 90 | Baseline (Day 1, Pre-dose), Day 90 | Analysis Population. Only those participants with data available at the specified data points were analyzed. | Percentage change | MEAN |
| PRIMARY | Change From Baseline in Maximum Leg Press Strength Following 1 Repetition Maximum (1-RM) at Day 28 | Baseline (Day 1, Pre-dose), Day 28 | Analysis Population. Only those participants with data available at the specified data points were analyzed. | Kilograms | MEAN |
| PRIMARY | Change From Baseline in Maximum Leg Press Strength Following 1 Repetition Maximum (1-RM) at Day 56 | Baseline (Day 1, Pre-dose), Day 56 | Analysis Population. Only those participants with data available at the specified data points were analyzed. | Kilograms | MEAN |
| PRIMARY | Change From Baseline in Maximum Leg Press Strength Following 1 Repetition Maximum (1-RM) at Day 90 | Baseline (Day 1, Pre-dose), Day 90 | Analysis Population. Only those participants with data available at the specified data points were analyzed. | Kilograms | MEAN |
| SECONDARY | Change From Baseline in Appendicular Lean Mass as Assessed by Dual-energy X-ray Absorptiometry (DXA) at Day 28 | Baseline (Day 1, Pre-dose), Day 28 | Analysis Population. Only those participants with data available at the specified data points were analyzed. | Kilograms | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03359473/outcomes